A potential solution involves using a combination of well-established biomarkers such as alpha fetoprotein (αFP), AFP L3, and des-gamma-carboxy prothrombin (DCP) within diagnostic panels, together with emerging markers including circulating tumor DNA (ctDNA), genomic glycosylation profiles, salivary metabolomics, and microRNAs [130]. Here, AFP is linked to neoplasm.